+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID07801508

Evaluation of Imaging, Safety, and Pharmacokinetics of 68GaGa-DWJ155 in Adults with Advanced Solid Tumors

Led by Novartis Pharmaceuticals · Updated on 2026-10-13

66

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the imaging characteristics, safety, distribution in the body, and pharmacokinetics of the radioligand imaging agent 68GaGa-DWJ155 in adults aged 18 and older with advanced solid tumors. The study focuses on patients with advanced gastroesophageal adenocarcinoma, hormone receptor-positivehuman epidermal growth factor receptor 2-negative advanced breast cancer, HER2-positive advanced breast cancer, triple-negative breast cancer, and advanced non-small cell lung cancer adenocarcinoma. This Phase I open-label study aims to understand how this imaging agent behaves in the body and how well it highlights tumors. Participants receive a single administration of 68GaGa-DWJ155 during a single-day imaging session. The study includes an imaging characterization part where biodistribution, tumor uptake, and radiation dosimetry are assessed to determine the optimal imaging timing for tumor visualization. If positive tumor uptake is observed, an expansion part may begin. The total study duration for each participant is approximately 32 days, including up to 28 days for screening and 3 days for safety follow-up after imaging. During the study, participants undergo assessments of standard uptake values in organs, normal tissue, and tumor lesions up to 180 minutes after injection. Safety is monitored by recording adverse events up to 3 days post-administration. Pharmacokinetic measurements include blood radioactivity levels and radiation doses. Participants are monitored closely for safety and imaging results during the short follow-up period.

CONDITIONS

Brief Title

A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here